44 related articles for article (PubMed ID: 9630838)
21. Interleukin-10 reduces natural killer (NK) sensitivity of tumor cells by downregulating NK target structure expression.
Tsuruma T; Yagihashi A; Hirata K; Torigoe T; Araya J; Watanabe N; Sato N
Cell Immunol; 1999 Dec; 198(2):103-10. PubMed ID: 10648124
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis.
Kundu N; Fulton AM
Cell Immunol; 1997 Aug; 180(1):55-61. PubMed ID: 9316639
[TBL] [Abstract][Full Text] [Related]
23. IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression.
Salazar-Onfray F; Petersson M; Franksson L; Matsuda M; Blankenstein T; Kärre K; Kiessling R
J Immunol; 1995 Jun; 154(12):6291-8. PubMed ID: 7759867
[TBL] [Abstract][Full Text] [Related]
24. [Expression of cell surface transformation-associated antigens TAAs on activated oncogene-transfected rat fibroblast and antitumor immunity by hosts].
Sato N; Yagihashi A; Konno A; Torigoe T; Kikuchi K
Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 2):653-61. PubMed ID: 2705790
[TBL] [Abstract][Full Text] [Related]
25. Dual effects of cytokines in regulation of MHC-unrestricted cell mediated cytotoxicity.
Reiter Z
Crit Rev Immunol; 1993; 13(1):1-34. PubMed ID: 8466640
[TBL] [Abstract][Full Text] [Related]
26. MHC class I antigens and immune surveillance in transformed cells.
Aptsiauri N; Cabrera T; Garcia-Lora A; Lopez-Nevot MA; Ruiz-Cabello F; Garrido F
Int Rev Cytol; 2007; 256():139-89. PubMed ID: 17241907
[TBL] [Abstract][Full Text] [Related]
27. MHC class I down-regulation: tumour escape from immune surveillance? (review).
Bubeník J
Int J Oncol; 2004 Aug; 25(2):487-91. PubMed ID: 15254748
[TBL] [Abstract][Full Text] [Related]
28. Re-expression of major histocompatibility complex (MHC) class I molecules on malignant tumor cells and its effect on host-tumor interaction.
Hui KM
Bioessays; 1989 Jul; 11(1):22-6. PubMed ID: 2673229
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of tumor and viral immune escape from natural killer cell-mediated surveillance.
Groth A; Klöss S; von Strandmann EP; Koehl U; Koch J
J Innate Immun; 2011; 3(4):344-54. PubMed ID: 21576922
[TBL] [Abstract][Full Text] [Related]
30. Natural killer cells in MHC class I deficient mice.
Salcedo M; Ljunggren HG
Chem Immunol; 1996; 64():44-58. PubMed ID: 8942071
[No Abstract] [Full Text] [Related]
31. Viral evasion of natural killer cells.
Orange JS; Fassett MS; Koopman LA; Boyson JE; Strominger JL
Nat Immunol; 2002 Nov; 3(11):1006-12. PubMed ID: 12407408
[TBL] [Abstract][Full Text] [Related]
32. Five decades of natural killer cell discovery.
Lanier LL
J Exp Med; 2024 Aug; 221(8):. PubMed ID: 38842526
[TBL] [Abstract][Full Text] [Related]
33. MHC class I gene expression by tumors: immunotherapeutic implications.
Weber JS; Jay G
Curr Top Microbiol Immunol; 1988; 137():140-7. PubMed ID: 3046844
[No Abstract] [Full Text] [Related]
34. Interleukin-10 and cancer.
Holland G; Zlotnik A
Cancer Invest; 1993; 11(6):751-8. PubMed ID: 8221208
[No Abstract] [Full Text] [Related]
35. Interleukin-10 reduces natural killer sensitivity and downregulates MHC class I expression on H-ras-transformed cells.
Tsuruma T; Yagihashi A; Torigoe T; Sato N; Kikuchi K; Watanabe N; Hirata K
Cell Immunol; 1998 Mar; 184(2):121-8. PubMed ID: 9630838
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
